Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Moleculin Biotech (MBRX) completed treatment of all 90 patients in Part A of its pivotal Phase 2/3 MIRACLE leukemia trial. The trial evaluates Annamycin with cytarabine for relapsed or refractory acute myeloid leukemia. Moleculin expects comprehensive Part A data in Q1 2027 to inform dose selection, with Part B planned for the first half of 2027.
Third-quarter net loss narrowed to $6.493 million from $25.399 million a year earlier, primarily reflecting the absence of the prior-year warrant-issuance loss. Research and development expenses rose to $4.488 million from $3.738 million. Cash and equivalents fell to $7.287 million at September 30, 2026, from $8.878 million at year-end 2025; nine-month operating cash use was approximately $21.7 million. A peer-reviewed analysis of 90 patients across five trials found no clinical or subclinical treatment-related heart toxicity.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointMIRACLE Part A completed treatment of all 90 patients with relapsed or refractory acute myeloid leukemia.
- Moderate point. Forward-looking: it has not happened yet and may not happen.MIRACLE comprehensive Part A data remain expected in Q1 2027.
- Moderate pointCardiac safety analysis across 90 patients in five trials found no clinical or subclinical treatment-related heart toxicity.
- Moderate pointThird-quarter net loss narrowed to $6.493 million from $25.399 million a year earlier.
- Minor pointPancreatic cancer preclinical findings suggest Annamycin activity partly involves cancer-killing CD8+ immune cells.
15 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.Pancreatic cancer physician-sponsored Annamycin trial initiation is planned for 1H 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.Third-line relapsed/refractory AML trial initiation is planned for 1H 2028.
- Minor point. Forward-looking: it has not happened yet and may not happen.Pediatric AML clinical study initiation is planned for 1H 2028.
- Minor point. Forward-looking: it has not happened yet and may not happen.MIRACLE Part B recruitment completion is targeted for 2H 2028.
- Minor point. Forward-looking: it has not happened yet and may not happen.MIRACLE second-line patients' primary efficacy data are targeted for 2H 2028.
- Minor point. Forward-looking: it has not happened yet and may not happen.Annamycin rolling approval-application submission is planned for 2028–2029, seeking accelerated approval based on complete remission.
- Minor pointWP1066 development continues through investigator-sponsored research, including a Phase 1B/2 glioblastoma trial with radiation.
- Minor pointNine-month net loss narrowed to $26.973 million from $49.112 million a year earlier.
- Minor pointThird-quarter loss per share narrowed to $9.59 from $340.43 a year earlier.
- Minor pointNine-month loss per share narrowed to $71.38 from $1,179.03 a year earlier.
- Minor pointGeneral and administrative expenses declined to $2.114 million quarterly and $6.705 million year-to-date, from $2.147 million and $6.715 million.
- Minor pointDepreciation and amortization fell to $8,000 quarterly and $24,000 year-to-date, from $21,000 and $81,000.
- Minor pointNine-month warrant fair-value gain increased to $10.798 million from $1.031 million a year earlier.
- Minor pointWarrant-issuance losses fell to zero quarterly and $15.158 million year-to-date, from $20.609 million and $30.962 million.
- Minor pointWarrant transaction costs fell to $12,000 quarterly and $707,000 year-to-date, from $530,000 and $1.737 million.
Negative
- Major pointOperating activities used approximately $21.7 million during the nine months ended September 30, 2026.
- Moderate pointCash and equivalents declined to $7.287 million at September 30, 2026, from $8.878 million at year-end 2025.
- Moderate pointNine-month research and development expenses rose to $15.317 million from $10.774 million a year earlier.
- Moderate point. Forward-looking: it has not happened yet and may not happen.MIRACLE Part B's planned 1H 2027 initiation follows dose selection informed by the Part A dataset.
- Minor pointThird-quarter research and development expenses rose to $4.488 million from $3.738 million a year earlier.
4 minor points
- Minor pointRevenue remained zero for both the third quarter and first nine months of 2026.
- Minor pointThird-quarter warrant fair-value gain decreased to $35,000 from $1.591 million a year earlier.
- Minor pointWarrant deemed dividends totaled $773,000 quarterly and $2.867 million year-to-date, versus none in either prior-year period.
- Minor pointNine-month net interest income declined to $15,000 from $96,000 a year earlier.
News Explained
At
Sources and calculations
- Moleculin third-quarter 2026 results release (2026-11-16)
- Moleculin third-quarter 2026 financial data (2026-09-30)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate $7,287,000 / ($8,970,000 / 92) = 74.7 days
Key Figures
- Part A patients treated
- 90 patients
- MIRACLE trial; treatment completed
- Part A data readout
- First quarter of 2027
- Comprehensive readout remains on track
- Part B initiation
- First half of 2027
- Planned following optimal dose selection
- Cardiac safety analysis
- 90 patients across five clinical trials
- Peer-reviewed analysis reported no clinical or subclinical cardiotoxicity at first interim analysis
- Research and development expenses
- Approximately $4.5 million vs. approximately $3.7 million
- Three months ended September 30, 2026 vs. same period in 2025
- Net loss
- Approximately $6.5 million vs. approximately $25.4 million
- Third quarter 2026 vs. same period in 2025; decrease primarily reflected absence of prior-year warrant-liability issuance loss
- Cash and cash equivalents
- Approximately $7.3 million vs. approximately $8.9 million
- September 30, 2026 vs. December 31, 2025
- Net cash used in operating activities
- Approximately $21.7 million
- Nine months ended September 30, 2026
Previous Earnings Reports
-
Reported interim MIRACLE remission findings and expected Part A completion; this update confirms treatment completion.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
aml medical
cytarabine medical
cardiotoxicity medical
nda regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Completed treatment of all 90 patients in Part A of the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (AML)
- Comprehensive Part A data readout remains on track for the first quarter of 2027, supporting optimal dose selection and planned initiation of Part B
- Annamycin's differentiated cardiac safety profile further supported by peer-reviewed analysis of 90 patients across five clinical trials, with no evidence of clinical or subclinical cardiotoxicity at first interim analysis
- New preclinical findings suggest Annamycin may help turn immunologically “cold” pancreatic tumors “hot,” supporting potential combination treatment approaches
HOUSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), reported on Friday the financial results for the third quarter ended September 30, 2026, and highlighted continued progress across its clinical development programs, including completion of treatment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin (also known as naxtarubicin) in relapsed or refractory acute myeloid leukemia (AML).
Moleculin continues to advance its lead clinical program following completion of treatment for all 90 patients in Part A of the MIRACLE trial. The Company remains on track to report comprehensive Part A data in the first quarter of 2027. These data are expected to support selection of the optimal Annamycin dose for advancement into Part B, which is currently planned to begin in the first half of 2027.
"We are approaching one of the most important milestones in Moleculin's development, and I believe our progress has positioned us to enter 2027 with meaningful momentum," said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. "Completing treatment of all 90 patients in Part A of our pivotal MIRACLE trial is a significant execution achievement. We are now focused on delivering the comprehensive dataset in the first quarter of 2027, which we expect will provide important insights into Annamycin's clinical activity, safety and optimal dose for advancement into Part B. We are also looking forward to releasing quantitative market research data soon, further supporting the commercial opportunity for Annamycin "
"What gives us confidence as we approach this readout is the totality of evidence generated to date," continued Mr. Klemp. "We have reported encouraging interim clinical findings, strengthened the scientific foundation supporting Annamycin's differentiated cardiac safety profile through independent, peer-reviewed analysis, and continued to execute against our pivotal development strategy. We believe Annamycin has the potential to address a meaningful treatment gap in AML, and the upcoming Part A results represent an important opportunity to further evaluate that potential. Our priority is clear: execute on the data readout, make informed development decisions and advance Annamycin toward its next critical milestones."
Recent Highlights
- Completed treatment for all 90 patients in Part A of the Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML. The Company remains on track for a comprehensive data readout in the first quarter of 2027. The full Part A dataset is expected to inform optimal dose selection for the planned initiation of Part B.
- Published a peer-reviewed analysis in Frontiers in Cardiovascular Medicine evaluating cardiac safety findings from 90 patients treated with Annamycin across five clinical trials in AML and metastatic soft tissue sarcoma. The analysis, independently evaluated by a cardio-oncology laboratory at Cleveland Clinic, found no clinical or subclinical evidence of treatment-related cardiotoxicity, including at cumulative Annamycin exposures exceeding traditional lifetime limits for conventional anthracyclines.
- Presented new preclinical data at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer indicating that Annamycin's antitumor activity in pancreatic cancer models is partially mediated by CD8+ T cell cytotoxicity. These findings suggest Annamycin may help expose immunologically “cold” tumors to immune attack, potentially supporting combination treatment approaches.
- Announced acceptance of data from the MIRACLE trial for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting. The presentation will highlight interim results from the pivotal Phase 2/3 trial in patients with relapsed or refractory AML.
Expected Milestones for the Annamycin Development Program
- Q1 2027: MIRACLE – Comprehensive Part A data readout following completion of treatment for all 90 patients
- 1H 2027: MIRACLE – Planned initiation of Part B following optimal dose selection
- 1H 2027: Planned initiation of physician-sponsored clinical trial evaluating Annamycin for pancreatic cancer
- 1H 2028: Planned initiation of third-line relapsed/refractory AML subject trial
- 1H 2028: Planned initiation of pediatric AML clinical study
- 2H 2028: Complete recruitment of Part B
- 2H 2028: Primary efficacy data for MIRACLE 2nd line subjects
- 2028-2029: Begin a rolling submission of a New Drug Application (NDA) for the treatment of R/R AML for accelerated approval on primary endpoint of CR from MIRACLE
Additional Pipeline Programs
Moleculin continues to support development activities for its WP1066 program through investigator-sponsored research, including a physician-sponsored Phase 1B/2 clinical trial evaluating WP1066 in combination with radiation for the treatment of glioblastoma. These programs complement Moleculin's primary focus on advancing Annamycin.
Third Quarter 2026 Financial Results
Research and development expenses were approximately
General and administrative expenses were approximately
Net loss for the third quarter of 2026 was approximately
For the nine months ended September 30, 2026, research and development expenses were approximately
As of September 30, 2026, Moleculin had cash and cash equivalents of approximately
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), has shown to be an efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company is conducting the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine (also referred to as “Ara-C”), together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway toward a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation: the potential efficacy and safety of Annamycin; the potential for Annamycin to be used in combination with immune checkpoint inhibitors or in indications other than AML; the timing and results of the comprehensive Part A data readout of the MB-108 trial; the planned initiation of Part B of the MIRACLE trial in the first half of 2027 and the expected timeline for completing Part B recruitment; the potential for the MB-108 trial to support a New Drug Application submission, including the anticipated rolling NDA submission during 2028-2029; the planned initiation of a third-line relapsed/refractory AML clinical study and a pediatric AML clinical study, each anticipated in the first half of 2028; the Company’s plans to sponsor an investigator-initiated clinical trial of Annamycin in pancreatic cancer; and the Company’s ability to secure additional financing to conduct its clinical trials. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the completion of the clinical trials described in this press release assumes the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
| Moleculin Biotech, Inc. | ||||||||
| Unaudited Condensed Consolidated Balance Sheets | ||||||||
| (in thousands) | September 30, 2026 | December 31, 2025 | ||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 7,287 | $ | 8,878 | ||||
| Prepaid expenses and other current assets | 1,124 | 808 | ||||||
| Total current assets | 8,411 | 9,686 | ||||||
| Intangible assets | 11,148 | 11,148 | ||||||
| Other non-current assets | 900 | 900 | ||||||
| Operating lease right-of-use asset | 223 | 314 | ||||||
| Furniture and equipment, net | 54 | 78 | ||||||
| Total assets | $ | 20,736 | $ | 22,126 | ||||
| Current liabilities: | ||||||||
| Accounts payable and other current liabilities | $ | 6,135 | $ | 6,854 | ||||
| Total current liabilities | 6,135 | 6,854 | ||||||
| Operating lease liability - long-term, net of current portion | 107 | 222 | ||||||
| Warrant liability - long term | 5 | 44 | ||||||
| Total liabilities | 6,247 | 7,120 | ||||||
| Total stockholders' equity | 14,489 | 15,006 | ||||||
| Total liabilities and stockholders' equity | $ | 20,736 | $ | 22,126 | ||||
| Unaudited Condensed Consolidated Statements of Operations | ||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||
| (in thousands, except share and per share amounts) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||
| Revenues | $ | - | $ | - | $ | - | $ | - | ||||||||||||
| Operating expenses: | ||||||||||||||||||||
| Research and development | 4,488 | 3,738 | 15,317 | 10,774 | ||||||||||||||||
| General and administrative | 2,114 | 2,147 | 6,705 | 6,715 | ||||||||||||||||
| Depreciation and amortization | 8 | 21 | 24 | 81 | ||||||||||||||||
| Total operating expenses | 6,610 | 5,906 | 22,046 | 17,570 | ||||||||||||||||
| Loss from operations | (6,610 | ) | (5,906 | ) | (22,046 | ) | (17,570 | ) | ||||||||||||
| Other income (loss): | ||||||||||||||||||||
| Gain from change in fair value of warrant liability | 35 | 1,591 | 10,798 | 1,031 | ||||||||||||||||
| Transaction costs allocated to equity and liability warrant issuances | (12 | ) | (530 | ) | (707 | ) | (1,737 | ) | ||||||||||||
| Loss on issuance of warrant liabilities | - | (20,609 | ) | (15,158 | ) | (30,962 | ) | |||||||||||||
| Other income, net | 36 | 16 | 125 | 30 | ||||||||||||||||
| Interest income, net | 58 | 39 | 15 | 96 | ||||||||||||||||
| Net loss | $ | (6,493 | ) | $ | (25,399 | ) | $ | (26,973 | ) | $ | (49,112 | ) | ||||||||
| Warrant deemed dividends | (773 | ) | - | (2,867 | ) | - | ||||||||||||||
| Net loss available to common stockholders | $ | (7,266 | ) | $ | (25,399 | ) | $ | (29,840 | ) | $ | (49,112 | ) | ||||||||
| Net loss per common share - basic and diluted | $ | (9.59 | ) | $ | (340.43 | ) | $ | (71.38 | ) | $ | (1,179.03 | ) | ||||||||
| Weighted average common shares outstanding - basic and diluted | 757,858 | 74,609 | 418,060 | 41,655 | ||||||||||||||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Moleculin report MIRACLE Part A results and start Part B?
Moleculin expects the comprehensive MIRACLE Part A readout in Q1 2027, with Part B planned to begin in 1H 2027. Treatment is complete for all 90 Part A patients. The company expects the dataset to inform selection of the Annamycin dose for Part B.
What were Moleculin Biotech's third-quarter 2026 financial results?
Moleculin reported a $6.493 million net loss, compared with $25.399 million a year earlier, and no revenue. Loss per common share was $9.59, versus $340.43. The narrower net loss primarily reflected the absence of the prior-year non-cash loss on issuing warrant liabilities.
Who independently evaluated Moleculin's Annamycin cardiac safety analysis?
A Cleveland Clinic cardio-oncology laboratory independently evaluated the cardiac safety analysis published in Frontiers in Cardiovascular Medicine. It covered patients with acute myeloid leukemia and metastatic soft tissue sarcoma, including cumulative Annamycin exposures exceeding traditional lifetime limits for conventional anthracyclines.